Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

BACKGROUND: Pulmonary hypertension patients experienced a high financial burden due to the high cost of drug therapy, high incidence of comorbidities and hospitalizations. Endothelin receptor antagonists (ERAs) in PAH treatment showed a high cost. While ambrisentan has been covered by medical insura...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Int J Gen Med
Main Authors: Chen, Jingyuan, Luo, Jun, Yang, Xiaojie, Luo, Peng, Chen, Yusi, Li, Zilu, Li, Jiang
Format: Artigo
Sprog:Inglês
Udgivet: Dove 2021
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8165300/
https://ncbi.nlm.nih.gov/pubmed/34079351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJGM.S304992
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker